This inventor holds 10 USPTO granted patents and 2 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2002-2011.
Company Filing History:
Years Active: 2002-2011
Title: The Innovative Contributions of Serge Plamondon
Introduction
Serge Plamondon is a notable inventor based in Ste-Catherine, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of HIV integrase inhibitors. With a total of 10 patents to his name, Plamondon's work has had a profound impact on the treatment of HIV infection and AIDS.
Latest Patents
Among his latest patents, Plamondon has developed a series of bicyclic pyrimidinone compounds that inhibit HIV integrase. This invention is crucial as it prevents viral integration into human DNA, making these compounds valuable for treating HIV infection and AIDS. One specific compound he has patented is N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, which also serves as an HIV integrase inhibitor.
Career Highlights
Plamondon's career is marked by his association with Bristol-Myers Squibb Company, where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approaches have led to the creation of effective treatments for those affected by HIV.
Collaborations
Throughout his career, Plamondon has collaborated with esteemed colleagues such as Jacques Banville and B Narasimhulu Naidu. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.
Conclusion
Serge Plamondon's contributions to the field of pharmaceuticals, particularly in HIV treatment, highlight his role as a leading inventor. His innovative patents and collaborations continue to pave the way for advancements in medical science.